Novo Nordisk/$NVO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Ticker
- $NVO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 66,700
- Headquarters
- Bagsvaerd, Denmark
- Website
- www.novonordisk.com
Novo Nordisk Metrics
BasicAdvanced
$190B
10.98
$3.84
-
$1.28
1.93%
Price and volume
Market cap
$190B
52-week high
$64.16
52-week low
$35.12
Average daily volume
12M
Dividend rate
$1.28
Financial strength
Current ratio
0.845
Quick ratio
0.629
Long term debt to equity
0.541
Total debt to equity
0.617
Dividend payout ratio (TTM)
45.85%
Interest coverage (TTM)
18.16%
Profitability
EBITDA (TTM)
26,363.425
Gross margin (TTM)
81.09%
Net profit margin (TTM)
33.92%
Operating margin (TTM)
43.40%
Effective tax rate (TTM)
21.77%
Revenue per employee (TTM)
$753,400
Management effectiveness
Return on assets (TTM)
16.29%
Return on equity (TTM)
58.38%
Valuation
Price to earnings (TTM)
10.983
Price to revenue (TTM)
3.72
Price to book
5.77
Price to tangible book (TTM)
11.85
Price to free cash flow (TTM)
27.507
Free cash flow yield (TTM)
3.64%
Free cash flow per share (TTM)
1.533
Dividend yield (TTM)
3.04%
Forward dividend yield
1.93%
Growth
Revenue change (TTM)
5.72%
Earnings per share change (TTM)
9.24%
3-year revenue growth (CAGR)
15.87%
10-year revenue growth (CAGR)
11.63%
3-year earnings per share growth (CAGR)
15.10%
10-year earnings per share growth (CAGR)
13.21%
3-year dividend per share growth (CAGR)
3.96%
10-year dividend per share growth (CAGR)
5.40%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Analyst projections of the future price of Novo Nordisk stock.
Bulls say / Bears say
The Wegovy pill is gaining traction: Q3 sales were DKK 5.39 billion, up 53% from Q2 and ahead of expectations, while Novo says it captured about 80% of US new-to-brand prescriptions for oral obesity drugs. (Reuters)
Novo raised its 2026 outlook for the third time after Q3 adjusted sales grew 4% and adjusted operating profit rose 27% at constant exchange rates, though the profit comparison benefited from lower prior-year restructuring costs. (Novo Nordisk)
A phase 3 CagriSema trial recorded 21% weight loss at 68 weeks, and a separate trial in people with type 2 diabetes showed greater weight loss than tirzepatide 5 mg. These results support Novo’s next-generation obesity pipeline. (Novo Nordisk)
US pricing pressure and competition remain a drag: Q3 US sales of injectable Wegovy fell 13% at constant exchange rates, and Novo’s outlook still assumes falling US sales. (Reuters)
Even after its third outlook increase, Novo expects 2026 adjusted sales and operating-profit growth of only between -2% and +2%, pointing to a near-flat year. (Novo Nordisk)
Novo’s long-term earnings remain exposed to its reliance on semaglutide: investors and analysts have called for a clearer strategy beyond the drug as key patents approach expiry in the early 2030s. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Upcoming events
No upcoming events
Novo Nordisk News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.